• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeting Advanced Glycation End Products in Cardiac Surgery: The Unexplored Alternative.心脏手术中针对晚期糖基化终末产物：未被探索的替代方案。
Res Cardiovasc Med. 2016 Mar 5;5(2):e31707. doi: 10.5812/cardiovascmed.31707. eCollection 2016 May.
2
Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease.糖尿病心血管疾病中针对晚期糖基化终产物（AGEs）的药物治疗方法
Res Cardiovasc Med. 2015 May 23;4(2):e26949. doi: 10.5812/cardiovascmed.4(2)2015.26949. eCollection 2015 May.
3
Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.阿尔吉林，一种糖基化终产物断裂剂，对慢性心力衰竭患者运动耐量和心功能的影响。
Eur J Heart Fail. 2011 Aug;13(8):899-908. doi: 10.1093/eurjhf/hfr067. Epub 2011 Jun 13.
4
Dietary advanced glycated end-products and medicines influence the expression of SIRT1 and DDOST in peripheral mononuclear cells from long-term type 1 diabetes patients.膳食晚期糖基化终产物和药物影响长期1型糖尿病患者外周血单个核细胞中SIRT1和DDOST的表达。
Diab Vasc Dis Res. 2018 Jan;15(1):81-89. doi: 10.1177/1479164117733918. Epub 2017 Oct 13.
5
Atorvastatin prevents advanced glycation end products (AGEs)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-γ).阿托伐他汀通过激活过氧化物酶体增殖物激活受体γ（PPAR-γ）来预防晚期糖基化终产物（AGEs）诱导的心脏纤维化。
Metabolism. 2016 Apr;65(4):441-53. doi: 10.1016/j.metabol.2015.11.007. Epub 2015 Nov 27.
6
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?晚期糖基化终末产物交联断裂剂阿格列汀与血管紧张素转换酶抑制剂联合治疗糖尿病：协同作用还是冗余作用？
Endocrinology. 2007 Feb;148(2):886-95. doi: 10.1210/en.2006-1300. Epub 2006 Nov 16.
7
Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol.晚期糖基化终末产物通过上调晚期糖基化终末产物受体增加巨噬细胞中的脂质积累：增加胆固醇的摄取、酯化并减少其流出。
Lipids Health Dis. 2016 Sep 19;15(1):161. doi: 10.1186/s12944-016-0334-0.
8
Targeting advanced glycation with pharmaceutical agents: where are we now?使用药物靶向晚期糖基化：我们目前进展如何？
Glycoconj J. 2016 Aug;33(4):653-70. doi: 10.1007/s10719-016-9691-1. Epub 2016 Jul 9.
9
Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.晚期糖基化终末产物交联断裂剂阿雷吉明作为糖尿病肾脏保护剂的作用。
Kidney Int Suppl. 2007 Aug(106):S54-60. doi: 10.1038/sj.ki.5002387.
10
Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications.糖基化与HMG-CoA还原酶抑制剂：对糖尿病及相关并发症的影响
Curr Diabetes Rev. 2019;15(3):213-223. doi: 10.2174/1573399814666180924113442.

引用本文的文献

1
Gold Nanoparticle-Based Detection of Low Molecular Weight AGEs from In Vitro Glycated Haemoglobin A0 Samples.基于金纳米颗粒检测体外糖化血红蛋白A0样品中的低分子量晚期糖基化终末产物
Nanoscale Res Lett. 2018 Dec 4;13(1):390. doi: 10.1186/s11671-018-2812-y.

本文引用的文献

1
Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease.糖尿病心血管疾病中针对晚期糖基化终产物（AGEs）的药物治疗方法
Res Cardiovasc Med. 2015 May 23;4(2):e26949. doi: 10.5812/cardiovascmed.4(2)2015.26949. eCollection 2015 May.
2
Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.通过皮肤自体荧光评估晚期糖基化终产物的组织蓄积水平：心血管疾病高危患者血管并发症的一种新标志物。
Int J Cardiol. 2015 Apr 15;185:263-8. doi: 10.1016/j.ijcard.2015.03.167. Epub 2015 Mar 17.
3
Association between preoperative plasma sRAGE levels and recovery from cardiac surgery.术前血浆 sRAGE 水平与心脏手术后恢复的关系。
Mediators Inflamm. 2013;2013:496031. doi: 10.1155/2013/496031. Epub 2013 Sep 5.
4
Soluble isoform of the receptor for advanced glycation end products as a biomarker for postoperative respiratory failure after cardiac surgery.可溶性晚期糖基化终产物受体同种型作为心脏手术后术后呼吸衰竭的生物标志物。
PLoS One. 2013 Jul 23;8(7):e70200. doi: 10.1371/journal.pone.0070200. Print 2013.
5
Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels.衰老导致的舒张功能障碍与心肌结构无关，但与血浆晚期糖基化终产物水平有关。
PLoS One. 2012;7(11):e49813. doi: 10.1371/journal.pone.0049813. Epub 2012 Nov 26.
6
Plasma sRAGE enables prediction of acute lung injury after cardiac surgery in children.血浆可溶性晚期糖基化终末产物受体能够预测儿童心脏手术后的急性肺损伤。
Crit Care. 2012 May 22;16(3):R91. doi: 10.1186/cc11354.
7
Surfactant protein B and RAGE increases in the plasma during cardiopulmonary bypass: a pilot study.表面活性蛋白 B 和 RAGE 在体外循环期间增加：一项初步研究。
Eur Respir J. 2011 Apr;37(4):841-7. doi: 10.1183/09031936.00045910. Epub 2010 Jul 22.
8
Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis.在患有钙化性主动脉瓣狭窄的患者中，循环可溶性晚期糖基化终产物受体水平降低。
Atherosclerosis. 2010 Jun;210(2):614-8. doi: 10.1016/j.atherosclerosis.2009.12.029. Epub 2010 Jan 4.
9
Different role of advanced glycation end products in pathology of transplanted heart in patients with or without diabetes mellitus type 2.
Transplant Proc. 2009 Oct;41(8):3185-9. doi: 10.1016/j.transproceed.2009.07.069.
10
Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?晚期糖基化终产物：一种作为心脏手术后结局预测指标的年龄生物标志物？
Exp Gerontol. 2007 Jul;42(7):668-75. doi: 10.1016/j.exger.2007.03.006. Epub 2007 Mar 27.

Targeting Advanced Glycation End Products in Cardiac Surgery: The Unexplored Alternative.

作者信息

Nenna Antonio, Nappi Francesco, Chello Massimo, Spadaccio Cristiano

机构信息

Department of Cardiovascular Surgery, Universita Campus Bio-Medico di Roma, Rome, Italy.

Department of Cardiac Surgery, Centre Cardiologique du Nord de Saint-Denis, Paris, France.

出版信息

Res Cardiovasc Med. 2016 Mar 5;5(2):e31707. doi: 10.5812/cardiovascmed.31707. eCollection 2016 May.

DOI:10.5812/cardiovascmed.31707
PMID:26949696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4756255/
Abstract
摘要